Genetic Testing Decision Aid
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT05470920
- Status
- Recruiting
Conditions
- Epithelial Ovarian Carcinoma
- Pancreas Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Electronic Decision Aid — BEHAVIORALDecision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires
- Pre-Test Genetic Counseling — BEHAVIORALReceive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
Study Details
This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer
Key Dates
- Start date
- Oct 14, 2022
- Status verified
- Aug 2025
- Primary completion
- Sep 30, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 350 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Electronic decision aid armReceive decision aid followed by an appointment with their oncologist.
- Active Comparator: Genetic counselor ArmReceive pretest counseling with a genetic counselor.
Primary Outcome Measure
Average change in knowledge survey score [ Time Frame: baseline (prior to participant completing either genetics sessions) to 1-week following session, approximately 2 weeks ]
Central Contacts
- Daniel C. Chung, MD(617) 726-8687
- Danielle A Lynch, BS(617) 726-1355
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02115 | Daniel C. Chung, MD (PRINCIPAL_INVESTIGATOR) |
| Mass General at North Shore Cancer Center | Danvers | Massachusetts | 01923 | Sara Bouberhan, MD Sara Bouberhan, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
Related Studies
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruiting · Guardant Health, Inc. · Birmingham, Alabama
- This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid TumorsPHASE1 · Recruiting · Zumutor Biologics Inc. · Boston, Massachusetts
- Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerPHASE2 · Recruiting · Loma Linda University · Loma Linda, California
- Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic CancerPHASE2 · Recruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina